Jiangxi Synergy Pharmaceutical Co., Ltd.
SZSE:300636.SZ
10.41 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 758.89 | 722.139 | 719.908 | 592.127 | 435.42 | 413.058 | 267.124 | 296.716 | 250.079 | 274.814 | 212.574 | 141.556 | 104.616 |
| Cost of Revenue
| 508.368 | 501.781 | 486.455 | 413.272 | 283.269 | 290.204 | 188.938 | 188.129 | 153.265 | 165.553 | 129.788 | 91.907 | 72.438 |
| Gross Profit
| 250.522 | 220.358 | 233.453 | 178.855 | 152.151 | 122.854 | 78.186 | 108.587 | 96.814 | 109.261 | 82.787 | 49.649 | 32.177 |
| Gross Profit Ratio
| 0.33 | 0.305 | 0.324 | 0.302 | 0.349 | 0.297 | 0.293 | 0.366 | 0.387 | 0.398 | 0.389 | 0.351 | 0.308 |
| Reseach & Development Expenses
| 59.447 | 63.151 | 60.912 | 39.022 | 35.301 | 36.333 | 25.359 | 12.52 | 12.74 | 14.362 | 9.398 | 7.054 | 6.572 |
| General & Administrative Expenses
| 9.766 | 7.017 | 4.79 | 5.415 | 3.798 | 5.372 | 13.439 | 4.291 | 3.757 | 5.788 | 3.854 | 17.013 | 15.163 |
| Selling & Marketing Expenses
| 16.909 | 26.255 | 18.47 | 18.029 | 13.853 | 13.073 | 11.356 | 9.469 | 10.415 | 10.387 | 9.479 | 8.054 | 5.946 |
| SG&A
| 26.675 | 32.137 | 23.26 | 23.444 | 17.651 | 18.445 | 24.795 | 13.76 | 14.172 | 16.175 | 13.333 | 25.067 | 21.109 |
| Other Expenses
| 52.999 | 0.268 | 25.092 | 17.103 | 9.798 | 7.02 | 0.044 | 1.843 | 9.299 | 6.73 | 3.828 | 3.536 | 3.331 |
| Operating Expenses
| 139.121 | 115.541 | 109.264 | 79.568 | 62.749 | 61.799 | 55.773 | 35.264 | 38.314 | 41.707 | 32.056 | 25.749 | 21.421 |
| Operating Income
| 111.401 | 112.232 | 106.332 | 88.341 | 78.249 | 51.681 | 26.282 | 72.76 | 58.389 | 65.847 | 41.635 | 15.971 | 5.73 |
| Operating Income Ratio
| 0.147 | 0.155 | 0.148 | 0.149 | 0.18 | 0.125 | 0.098 | 0.245 | 0.233 | 0.24 | 0.196 | 0.113 | 0.055 |
| Total Other Income Expenses Net
| 3.289 | 0.268 | -0.183 | 0 | -6.732 | -3.832 | 14.538 | 1.843 | 9.125 | 6.73 | -4.421 | -4.423 | 3.168 |
| Income Before Tax
| 114.69 | 112.5 | 106.15 | 88.341 | 78.059 | 51.683 | 26.325 | 74.603 | 67.514 | 72.577 | 45.462 | 19.507 | 8.898 |
| Income Before Tax Ratio
| 0.151 | 0.156 | 0.147 | 0.149 | 0.179 | 0.125 | 0.099 | 0.251 | 0.27 | 0.264 | 0.214 | 0.138 | 0.085 |
| Income Tax Expense
| 8.106 | 6.517 | 5.482 | 7.221 | 8.008 | 3.374 | 1.795 | 9.146 | 9.518 | 9.698 | 6.254 | 2.623 | 0.869 |
| Net Income
| 106.584 | 105.983 | 100.667 | 81.12 | 70.051 | 48.309 | 24.531 | 65.458 | 57.996 | 62.879 | 39.208 | 16.884 | 8.028 |
| Net Income Ratio
| 0.14 | 0.147 | 0.14 | 0.137 | 0.161 | 0.117 | 0.092 | 0.221 | 0.232 | 0.229 | 0.184 | 0.119 | 0.077 |
| EPS
| 0.25 | 0.28 | 0.31 | 0.26 | 0.23 | 0.16 | 0.079 | 0.23 | 0.25 | 0.29 | 0.32 | 0.14 | 0.055 |
| EPS Diluted
| 0.25 | 0.28 | 0.29 | 0.24 | 0.23 | 0.16 | 0.079 | 0.22 | 0.25 | 0.29 | 0.32 | 0.14 | 0.055 |
| EBITDA
| 247.598 | 192.542 | 181.478 | 146.083 | 139.717 | 99.059 | 50.187 | 96.239 | 72.719 | 80.843 | 65.952 | 23.9 | 10.756 |
| EBITDA Ratio
| 0.326 | 0.267 | 0.252 | 0.247 | 0.321 | 0.24 | 0.188 | 0.324 | 0.291 | 0.294 | 0.31 | 0.169 | 0.103 |